Virtual Library

Start Your Search

Y. Liu



Author of

  • +

    P1.07 - Immunology and Immunotherapy (ID 693)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Immunology and Immunotherapy
    • Presentations: 1
    • +

      P1.07-006 - Altered Expression of Programmed Death-1 Receptor (PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant Chemotherapy in Lung Cancer (ID 7930)

      09:30 - 09:30  |  Author(s): Y. Liu

      • Abstract
      • Slides

      Background:
      Immunotherapy is a new research direction in the treatment of lung cancer. PD1/PD-L1, PD-L2 pathway as representative of the immune checkpoint, play critical roles in the development and progression of cancer. And the expression of PD-1, PD-L1, PD-L2 were associated with therapeutic effect. Many studys have shown that many factors may effect the expression of PD1, PD-L1, PD-L2, such as chemotherapy. The present study aims to examine the impact of neo-adjuvant chemotherapy (NAC) on PD-1, PD-L1, PD-L2 expression in lung cancer.

      Method:
      In this study, tumor samples were obtained from 26 patients who confirmed primary lung cancer prior to and after NAC(platinum-based)from June, 2009 to May, 2016 in the First Hospital of Jilin University. Expression of PD-1, PD-L1, PD-L2 in lung cancer tumor specimens were assessed by immunohistochemistry (IHC). Using 5%, 10%, 20%, 30%, 50% expression threshold to define PD-1, PD-L1, PD-L2 positive status, respectively. The variation of PD-1, PD-L1, PD-L2 in prior to and after NAC were evaluated by Matching chi-square test. Besides that, Spearman's rank correlation and non-parametric test were used to calculate the relationship between the changes of PD-1, PD-L1, PD-L2 and tumor shrinkage rate, interval from the end of NAC to operation, pathological type, gender, smoking or not. P value < 0.05 was considered statistically significant.

      Result:
      Using 5%, 10%, 20% expression threshold to define PD-L1 positive status, 65.4%(17/26), 53.8%(14/26), 42.3%(11/26) were found to be PD-L1 positive prior to NAC, and 92.3% (24/26), 80.8%(21/26), 69.2%(18/26) expressed positively after NAC, PD-L1 was up-regulated after NAC(p=0.003, p=0.016, p=0.016), however, there were no obviously statistical significance about the expression of PD-L1(p>0.05)when using 30%, 50% expression threshold. The expression of PD1, PD-L2 were not show any statistical significance before and after NAC(p>0.05). Furthermore, there were no relationship between the changes of PD-1, PD-L1, PD-L2 and pathological type, interval from the end of NAC to operation, gender, smoking or not (p>0.05).Figure 1



      Conclusion:
      The expression of PD-L1 was up-regulated after NAC when using 5%, 10%, 20% expression threshold, there were obviously statistical significance. No correlations existed between the variation of PD-1, PD-L1, PD-L2 and tumor shrinkage rate, interval from the end of NAC to operation, pathological type, gender, smoking or not.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.